← Leaderboards
Max Parven Horowitz
University Of Pittsburgh At Pittsburgh
$183,664
Attributed
$183,664
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.2K · FY2010–13$50K$37.5K$25K$12.5K$0
'10
'11
'12
'13
Funding mix
By agency
NIH$183,664 · 1
By mechanism
F30$183,664 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jun Chen$22,616,112
- Laurie H Sanders$3,931,599
- Sarah B Berman$4,791,994
- Michael J Zigmond$14,942,841
- Ronald L Hamilton$2,372,992
Others in their field
Top investigators on “Parkinson Disease”
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$92,426,001
- David M Anderson · University Of Washington$40,483,703
- Daniel M Corcos · Northwestern University$37,632,589
- Joel Synes Perlmutter · Washington University$37,192,743
- Jerrold L Vitek · University Of Minnesota$35,135,315
- Joseph B Martin · Harvard University (Medical School)$26,652,023
Research focus
Parkinson DiseaseProtein IsoformsIronNovel Therapeutic InterventionPesticidesPreventIn VivoAttenuatedBrainNeurodegenerative DisordersDopaminergic NeuronAnimal ModelGata2 Transcription FactorAffectCytotoxicAmericanGene SilencingGene TherapyGenetic TranscriptionHematopoiesisDisease ProgressionMediatingIn VitroPublic Health Medicine (Field)
Grant awards (4)
GATA2 as a therapeutic target in Parkinson's disease$43,252
F30 · FY2013 · ES · contact PI
GATA2 as a therapeutic target in Parkinson's disease$47,232
F30 · FY2012 · ES · contact PI
GATA2 as a therapeutic target in Parkinson's disease$46,800
F30 · FY2011 · ES · contact PI
GATA2 as a therapeutic target in Parkinson's disease$46,380
F30 · FY2010 · ES · contact PI